Summit Therapeutics PLC | Ownership
Companies that own Summit Therapeutics PLC
Lansdowne Partners (UK) LLP
13,160,170
16.02%
2,083,000
0.04%
04/30/2018
Hargreave Hale Ltd.
3,658,400
4.46%
-1,881,982
0.02%
06/27/2018
SEB Investment Management AB
2,294,000
2.79%
2,294,000
0%
08/02/2018
Polar Capital LLP
2,244,933
2.73%
-1,240
0%
07/31/2018
Baillie Gifford & Co.
1,625,078
1.98%
0
0%
04/30/2018
Hargreaves Lansdown Stockbrokers Ltd.
1,568,000
1.91%
309,000
0%
08/02/2018
United Nations Joint Staff Pension Fund
1,326,000
1.62%
0
0.04%
08/02/2018
Hargreaves Lansdown Asset Management Ltd.
1,020,000
1.24%
332,000
0.01%
08/02/2018
HSBC Bank Plc (Market-Maker)
871,000
1.06%
512,000
0.08%
08/02/2018
Jupiter Asset Management Ltd.
750,000
0.91%
0
0%
02/28/2018
| Address |
136a Eastern Avenue
Abingdon Oxfordshire OX14 4SB
United Kingdom
|
|
Employees
|
- |
| Website |
http://summitplc.com |
| Updated |
07/08/2019 |
| Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom. |
